Aldeyra Therapeutics, Inc.

As of June 30, 2026, Aldeyra Therapeutics, Inc. carries a market capitalization of 112.20M, placing it among publicly traded companies globally. Its enterprise value stands at 72.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Aldeyra Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Aldeyra Therapeutics, Inc. has 60.32M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Aldeyra Therapeutics, Inc. maintains a current ratio of 4.91, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.38, indicating conservative leverage, while an interest coverage ratio of -16.76 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Aldeyra Therapeutics, Inc. posted a negative return on equity (ROE) of -49.48, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -34.80, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 8.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Aldeyra Therapeutics, Inc.'s stock has declined approximately 86.95% over the past 52 weeks. The 50-day moving average sits at 1.10, while the 200-day moving average is 2.03.

Over the twelve months ended June 30, 2026, Aldeyra Therapeutics, Inc. generated - - in revenue and converted that into -20.18M in net income, yielding earnings per share of -0.34. EBITDA reached -20.83M, while operating income came in at -21.07M.

As of June 30, 2026, Aldeyra Therapeutics, Inc. holds 39.47M in cash and equivalents against 125,559.16 in total debt, resulting in a net debt position of -39.47M. Total book value stands at 33.16M, with working capital of 33.02M providing operational flexibility.

Aldeyra Therapeutics, Inc. produced -19.27M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -17.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 11.79, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Aldeyra Therapeutics, Inc. shareholders.

As of June 30, 2026, Aldeyra Therapeutics, Inc. has an Altman Z-Score of -7.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.